PHARMAXIS LIMITED (PXS)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

PXS - PHARMAXIS LIMITED

Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.08

18 Aug
2022

0.000

OPEN

$0.08

0.000

HIGH

$0.08

170,772

LOW

$0.08

TARGET
$0.25 212.5% upside
OTHER COMPANIES IN THE SAME SECTOR
CUV . ACR . AHZ . CSL . IDT . IVX . MSB . MYX . RNO . OSL . TFC . TIS . KZA . AGH . FTT . PAR . ADO . PYC . RAC . RCE . ZNO . OCC . AVH . LGP . SPL . ARX . AFP . 1AD . TLX . PNV . MVP . BNO . NXS . GSS . EOF . NEU . PAL . PBP . BOT . IMU . MDC . IMM . HXL . MXC . OPT . ANP . BIO .
FNARENA'S MARKET CONSENSUS FORECASTS
PXS: 1
Title FY21
Actual
FY22
Actual
FY23
Forecast
FY24
Forecast
EPS (cps) xxx - 0.4 - 2.5 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

0.00

Estimated Dividend Growth
(Average Of Past Three Years)

 %

Amount Invested

Tell Me The Dividend After This Many Years

Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2022 FactSet UK Limited. All rights reserved
Title 201720182019202020212022
EPS Basic xxxxxxxxxxxxxxx-0.4
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx9.8 M
Book Value Per Share xxxxxxxxxxxxxxx
Net Operating Cash Flow xxxxxxxxxxxxxxx M
Net Profit Margin xxxxxxxxxxxxxxx-19.77 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201720182019202020212022
Return on Capital Employed xxxxxxxxxxxxxxx-28.28 %
Return on Invested Capital xxxxxxxxxxxxxxx-17.36 %
Return on Assets xxxxxxxxxxxxxxx-6.57 %
Return on Equity xxxxxxxxxxxxxxx-28.28 %
Return on Total Capital xxxxxxxxxxxxxxx-164.14 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

This is work in progress. Bear with us. It'll be amazing.

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

17/08/2022

1

Speculative Buy

$0.25

212.50%

Following FY22 results for Pharmaxis, Morgans likes the sound cash position though lowers its target to $0.25 from $0.58 on a deferral to FY26 from FY25 of the licensing transaction for the Myelofibrosis program.

Modest upgrades are made to the broker's FY23 forecasts after including $7m from the exercise of the option by Aptar Pharma to acquire the Pharmaxis Orbital technology, offset by lower Bronchitol sales.

The Speculative Buy rating is unchanged.

FORECAST
Morgans forecasts a full year FY23 dividend of 0.00 cents and EPS of minus -2.50 cents.
Morgans forecasts a full year FY24 dividend of 0.00 cents and EPS of minus -2.80 cents.

PXS STOCK CHART